title: Reversal of heart failure remodeling with age.
abstract: Since heart failure is a major cause of morbidity in the elderly, we studied the effect of up-titrated heart failure therapy in older vs. younger individuals on symptoms and left ventricular (LV) function over 1 year. Seventy-one patients with heart failure and an LV ejection fraction < or =35% were enrolled and were followed with echocardiography at baseline and at 1 year. Young patients were born in or after 1935 (n=48; 51.7+/-9.1 years); middle-aged were born between 1925-1934 (n=14; 69.7+/-2.8 years); and older patients in or prior to 1924 (n=9; 80.5+/-3.3 years). Baseline LV ejection fraction was 18%+/-7%, LV end-diastolic diameter 6.9+/-0.9 cm, and New York Heart Association class was 2.6+/-1.0, equivalent for all groups. On medical therapy, at 12 months, LV ejection fraction improved only for the young and middle-aged (36%+/-14% and 37%+/-17%; p=0.002), but not for the older patients (22%+/-7%; p=NS). Reductions in LV end-diastolic diameter and mitral regurgitation were significant only for the young. However, New York Heart Association status improved similarly for all groups (1.6+/-0.8; p<0.001), as did heart failure hospitalizations (p<0.0001). Although all groups tolerated intensified heart failure therapy, only the young and middle-aged improved LV remodeling. However, older patients experienced equivalent significant improvements in heart failure symptoms and hospitalizations.
authors.affiliation: Michigan Institute for Heart Failure and Transplant Care, Botsford General Hospital, Farmington Hills, MI, USA. Blevine@WAAHS.org
authors.forename: T Barry
authors.initials: TB
authors.lastname: Levine
authors.forename: Arlene B
authors.initials: AB
authors.lastname: Levine
authors.forename: Janet
authors.initials: J
authors.lastname: Bolenbaugh
authors.forename: Pamela R
authors.initials: PR
authors.lastname: Green
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004452:Echocardiography; D005260:Female; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012074:Remission Induction; D013997:Time Factors; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors